Screener
Gilead Sciences GILD Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept gild:OtherEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestments.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Equity method investment in Lakefront Biotherapeutics NV (“Lakefront”) (formerly known as Galapagos NV) – fair value option | 500 | 551 |
| Equity method investment in Arcus Biosciences, Inc. – fair value option | 969 | 749 |
| Other equity method investments – fair value option(1) | 171 | 183 |
| Other | 63 | 499 |
| Other long-term assets | 431 | 386 |
| Equity method investments and other equity securities without readily determinable fair values: | ||
| Other long-term assets(2) | 295 | 393 |
| Total | $3,992 | $8,909 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's other non-current assets?
- Gilead Sciences (GILD) reported other non-current assets of $295M in Q2 2026.
- How has Gilead Sciences's other non-current assets changed year-over-year?
- Gilead Sciences's other non-current assets decreased by 20.1% year-over-year, from $369M to $295M.
- What is the long-term trend for Gilead Sciences's other non-current assets?
- Over 5 years (2020 to 2025), Gilead Sciences's other non-current assets has grown at a -41.4% compound annual growth rate (CAGR), from $5.71B to $393M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Gilead Sciences's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude